COMBINATION OF A BCL-2 INHIBITOR AND A HYPOMETHYLATING AGENT FOR TREATING CANCERS, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF

COMBINATION OF A BCL-2 INHIBITOR AND A HYPOMETHYLATING AGENT FOR TREATING CANCERS, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF

A combination comprising a Bcl-2 inhibitor with a hypomethylating agent, uses in the treatment of cancers and pharmaceutical compositions thereof. The Bcl-2 inhibitor is 5-(5-chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phenyl)-N-(5-cyano-1,2-dimethyl-1H-pyrrol-3...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: COOPER, Michael, Robert, DESSEIN, Emmelyne, MAHNKE, Lisa
Format: Patent
Sprache:eng ; fre ; ger
Schlagworte:
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:A combination comprising a Bcl-2 inhibitor with a hypomethylating agent, uses in the treatment of cancers and pharmaceutical compositions thereof. The Bcl-2 inhibitor is 5-(5-chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phenyl)-N-(5-cyano-1,2-dimethyl-1H-pyrrol-3-yl)-N-(4-hydroxyphenyl)-1,2-dimethyl-1H-pyrrole-3-carboxamide and the hypomethylating agent is selected from decitabine, azacitidine and guadecitabine.